Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA ...

Britain's blue-chip FTSE 100 kicked off the week higher on Monday, boosted by heavyweight healthcare and defence stocks, on ...

ASCO’s updated guidelines for advanced ovarian cancer emphasize health equity and provide new recommendations for HIPEC while ...

Study cohort began collecting data on newborns through adulthood, and may offer objective clues on asthma and COPD disease ...

AstraZeneca will buy U.S. biotech firm FibroGen's China unit for about $160 million, in its latest deal to boost its presence ...

(Reuters) -AstraZeneca will buy longtime partner FibroGen's China unit for about $160 million to gain rights to its anemia ...

Kiniksa’s actions leave it focused on a cardiovascular disease pipeline led by the IL-1 antagonist KPL-387. The program is ...

Learn more about whether AstraZeneca PLC or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor ...

AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...

DURIPANC is an investigator-initiated, exploratory, open-label, single-center study in the Netherlands at the Erasmus Medical ...

Shares of AstraZeneca PLC (LON:AZN – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...